Several other EZH2 inhibitors are in ongoing clinical studies for treatment of NHL and include CPI-0209 (NCT04104776), HH2853 (NCT04390737), and PF-06821497 (NCT03460977; Table 3) [86, 87]. This evidence concerns the gene EZH2 and non-Hodgkin lymphoma.